Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT02855411 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02855411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02855411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Terminated
Start date
August 29, 2016
Completion date
September 26, 2016
Enrollment
35 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment associated with schizophrenia (cias)